Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 22, 2024 | November 27, 2024 |
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director · Chairman & CEO · 10% owner | June 30, 2026 | July 01, 2026 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director · Chief Executive Officer | January 01, 2019 | January 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date November 22, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-22 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 45,000 |
Reported balance
After 2024-11-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-22 · Grant · Acquired 45,000 · Balance 45,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-22 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 40,000 |
Reported balance
After 2024-11-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-22 · Grant · Acquired 40,000 · Balance 40,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 30,000 |
Reported balance
After 2024-11-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-22 · Grant · Acquired 30,000 · Balance 30,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-11-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 24,000 |
Reported balance
After 2024-11-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-11-22 · Grant · Acquired 24,000 · Balance 24,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Nuvectis Pharma, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,688,424 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 12,500 · Balance 3,688,424 F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.
F2: Includes shares of restricted common stock.
UroGen Pharma Ltd.
Report date January 01, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,113 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 38,113 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.55 · Expires 2027-06-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.67 · Expires 2028-01-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017.
F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 66,346 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2021-03-08 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Disposition to issuer · Disposed 9,034 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2022-03-09 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Disposition to issuer · Disposed 18,070 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-10 · Disposition to issuer · Disposed 24,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F2: All options were vested and exercisable as of the effective time of the merger.
F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 17:39 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 12,500 | $20.00 | $250,000.00 |
DisclosureSEC source: 0001104659-26-079792 · tm2619552-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,688,424 F1 · shares: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 21:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002500 · tm262288-3_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,675,924 F1 · shares: The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Bentsur's continued service on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 13:01 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,000 | $5.72 | $28,600.00 |
DisclosureSEC source: 0001104659-25-107423 · tm2530379-3_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,525,924 F1 · balance_after: Includes 676,759 shares of restricted stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:09 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000909 · tm251747-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,520,924 F1 · shares: The 250,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Bentsur's continued service on such dates. F2 · balance_after: Includes 676,759 shares of restricted stock. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 13:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 4,500 | $4.65 | $20,925.00 |
DisclosureSEC source: 0001104659-24-131541 · tm2432030-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,270,924 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $4.64 to $4.67. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 24,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 12 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 24,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 11 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 10 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $5.32 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 9 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 8 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 25,000 | Not disclosed Strike: $5.45 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 7 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 6 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $6.87 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 5 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 4 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 40,000 | Not disclosed Strike: $6.28 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Options (Right to buy) · Derivative | 45,000 | Not disclosed Strike: $0.54 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 22, 2024 Filed Nov 27, 2024 02:55 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Disposition to issuerStock Options (Right to buy) · Derivative | 45,000 | Not disclosed Strike: $1.53 | Not disclosed |
DisclosureSEC source: 0001493152-24-047888 · ownership.xml · derivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F1 · price: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. F2 · derivative.expiration_date: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 13:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 20,000 | $4.92 | $98,400.00 |
DisclosureSEC source: 0001104659-24-119976 · tm2428650-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,266,424 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $4.89 to $5.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:16 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,940 | $6.74 | $13,075.60 |
DisclosureSEC source: 0001104659-24-061674 · tm2414527-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,246,424 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $6.65 to $6.94. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| May 10, 2024 Filed May 13, 2024 12:51 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,000 | $6.40 | $12,800.00 |
DisclosureSEC source: 0001104659-24-060263 · tm2414233-3_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,244,484 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $6.31 to $6.44. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 01:01 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001493152-24-010868 · ownership.xml · derivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2024, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,000 | $10.29 | $51,450.00 |
DisclosureSEC source: 0001104659-24-035902 · tm249189-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,242,484 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| October 10, 2023 Filed Oct 12, 2023 20:05 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 640 | $11.08 | $7,091.20 |
DisclosureSEC source: 0001104659-23-108814 · tm2328332-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,237,484 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.81 to $11.6243. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| October 09, 2023 Filed Oct 10, 2023 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 830 | $11.19 | $9,287.70 |
DisclosureSEC source: 0001104659-23-107889 · tm2328102-1_4.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,236,844 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.80 to $11.5859. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 250 | $11.27 | $2,817.50 |
DisclosureSEC source: 0001104659-23-107889 · tm2328102-1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,236,014 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.96 to $11.35. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 12:37 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,400 | $11.09 | $15,526.00 |
DisclosureSEC source: 0001104659-23-107367 · tm2327960-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,235,764 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.7875 to $11.32. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 12:37 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,820 | $10.95 | $19,929.00 |
DisclosureSEC source: 0001104659-23-107367 · tm2327960-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,234,364 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.76 to $11.236. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| August 16, 2023 Filed Aug 16, 2023 20:05 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 115 | $15.15 | $1,742.25 |
DisclosureSEC source: 0001104659-23-092539 · tm2323962-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,232,544 F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| August 15, 2023 Filed Aug 16, 2023 20:05 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 235 | $14.34 | $3,369.90 |
DisclosureSEC source: 0001104659-23-092539 · tm2323962-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,232,429 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.25 to $14.44. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| August 11, 2023 Filed Aug 11, 2023 22:07 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 180 | $14.66 | $2,638.80 |
DisclosureSEC source: 0001104659-23-090650 · tm2323608d1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,232,194 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| August 08, 2023 Filed Aug 11, 2023 22:07 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 120 | $14.83 | $1,779.60 |
DisclosureSEC source: 0001104659-23-090650 · tm2323608d1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,232,014 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 21, 2023 Filed Jul 24, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 225 | $14.85 | $3,341.25 |
DisclosureSEC source: 0001104659-23-083472 · tm2321778-2_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,894 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.55 to $15.14. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 110 | $15.06 | $1,656.60 |
DisclosureSEC source: 0001104659-23-083472 · tm2321778-2_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,669 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 19, 2023 Filed Jul 20, 2023 10:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 200 | $14.33 | $2,866.00 |
DisclosureSEC source: 0001104659-23-082535 · tm2321693-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,559 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 12:34 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 150 | $15.03 | $2,254.50 |
DisclosureSEC source: 0001104659-23-081834 · tm2321526-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,359 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 07, 2023 Filed Jul 18, 2023 12:34 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 110 | $16.19 | $1,780.90 |
DisclosureSEC source: 0001104659-23-081834 · tm2321526-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,209 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 12:03 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 320 | $14.88 | $4,761.60 |
DisclosureSEC source: 0001104659-23-078941 · tm2320821-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,231,099 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.86 to $14.90. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 12:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 750 | $16.50 | $12,375.00 |
DisclosureSEC source: 0001104659-23-075030 · tm2319737-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,230,779 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 12:42 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $17.88 | $8,940.00 |
DisclosureSEC source: 0001104659-23-073568 · tm2319376-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,230,029 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 01:28 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 120 | $17.53 | $2,103.60 |
DisclosureSEC source: 0001104659-23-069566 · tm2318125-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,229,529 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 01:28 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 230 | $17.41 | $4,004.30 |
DisclosureSEC source: 0001104659-23-069566 · tm2318125-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,229,409 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 330 | $17.28 | $5,702.40 |
DisclosureSEC source: 0001104659-23-066844 · tm2317506-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,229,179 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| May 24, 2023 Filed May 26, 2023 13:29 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 200 | $17.49 | $3,498.00 |
DisclosureSEC source: 0001104659-23-065198 · tm2317124-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,228,849 F1 · balance_after: Includes 426,759 shares of restricted stock. Read SEC document |
| May 16, 2023 Filed May 18, 2023 11:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 320 | $17.03 | $5,448.00 |
DisclosureSEC source: 0001104659-23-062078 · tm2316170-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,228,649 F2 · price: Includes 216,759 shares of restricted stock and 210,000 restricted stock units. F1 · balance_after: Reflects the weighted average purchase price. The range of prices for the shares purchased was $16.95 to $17.15. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 12:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 230 | $12.13 | $2,789.90 |
DisclosureSEC source: 0001104659-23-036892 · tm2310605-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,228,329 F1 · balance_after: Includes 96,759 shares of restricted stock and 330,000 restricted stock units. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 480 | $12.08 | $5,798.40 |
DisclosureSEC source: 0001104659-23-035861 · tm2310299-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,228,099 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $11.95 to $12.39. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 330,000 restricted stock units. Read SEC document |
| March 20, 2023 Filed Mar 21, 2023 20:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 2,300 | $6.48 | $14,904.00 |
DisclosureSEC source: 0001493152-23-008362 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,736 Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 480 | $10.91 | $5,236.80 |
DisclosureSEC source: 0001104659-23-033354 · tm239792-2_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,227,619 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.605 to $11.10. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 330,000 restricted stock units. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 20:45 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,680 | $10.85 | $18,228.00 |
DisclosureSEC source: 0001104659-23-033354 · tm239792-2_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,227,139 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $10.71 to $10.99. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 330,000 restricted stock units. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 22:04 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003864 · tm232835-2_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,225,459 F1 · shares: The restricted stock units will vest according to the following schedule: one-third on each of 01/12/2024, 01/12/2025, and 01/12/2026. F2 · balance_after: Includes 96,759 shares of restricted stock and 330,000 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.